Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path to market for a second after BTK inhibitor LOXO-305 after reporting promising data at ...

To QB or not to QB? That was the question Eli Stowers asked himself as the 2023 college football season approached for New Mexico State. The question answered itself. The answer not to QB.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

In contrast to all that, many investors prefer to focus on companies like Eli Lilly (NYSE:LLY), which has not only revenues, but also profits. While profit isn't the sole metric that should be ...

Shelby Knowles / Bloomberg via Getty Images Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive ...

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...

Eli Lilly (LLY) stated: “In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit ...

Eli Puretz wants others to avoid the mistake he made. Puretz, a 29-year old real estate investor, is facing a sentence of five years in prison for his role in a multi-million-dollar commercial ...